Staging/H&P/Imaging Algorithm

STAGING/H&P/IMAGING

Non-metastatic CRPC

Index Patient 1
- Clinicians should recommend observation with continued androgen deprivation
- Clinicians may offer treatment with first-generation anti-androgens (flutamide, bicalutamide and nilutamide) or first-generation androgen synthesis inhibitors (ketoconazole + steroid) to select patients unwilling to accept observation

Clinicians should NOT offer systemic chemotherapy or immunotherapy outside the context of a clinical trial

Index Patient 2
- Clinicians should offer abiraterone + prednisone, docetaxel systemic chemotherapy or sipuleucel-T immunotherapy
- Clinicians may offer first-generation anti-androgen therapy, ketoconazole + steroid or observation to patients who do not want or cannot have one of the previously listed standard treatments.

Guideline Statements on Bone Health for all Index Patients
- Clinicians should offer preventative treatment (e.g. supplemental calcium, Vitamin D) for fractures and skeletal related events to CRPC patients
- Clinicians may choose either denosumab or zoledronic acid when selecting a preventative treatment for skeletal related events for CRPC patients with bony metastases

Clinicians should NOT offer treatment with either estramustine or sipuleucel-T

Index Patient 3
- Clinicians should offer docetaxel
- Clinicians may offer abiraterone + prednisone
- Clinicians may offer ketoconazole + steroid, mitoxantrone or radionuclide therapy to patients who do not want or cannot have one of the previously listed treatments

Clinicians should NOT offer treatment with either estramustine or sipuleucel-T

Index Patient 4
- Clinicians may offer treatment with abiraterone + prednisone
- Clinicians may offer treatment with ketoconazole + steroid or radionuclide therapy to patients who are unable or unwilling to receive abiraterone + prednisone
- Clinicians may offer docetaxel or mitoxantrone chemotherapy in select cases, specifically when performance status is directly related to the cancer

Clinicians should NOT offer systemic chemotherapy or immunotherapy

Index Patient 5
- Clinicians should offer treatment with abiraterone + prednisone, cabazitaxel or enzalutamide; if the patient received abiraterone + prednisone prior to docetaxel chemotherapy, cabazitaxel or enzalutamide should be offered
- Clinicians may offer ketoconazole + steroid if one of the previously listed standard treatments is unavailable
- Clinicians may offer retreatment with docetaxel to patients who were benefiting at the time of discontinuation (due to reversible side effects) of docetaxel chemotherapy

Index Patient 6
- Clinicians should offer palliative care
- Clinicians may offer treatment with abiraterone + prednisone, enzalutamide, ketoconazole + steroid or radionuclide therapy

Clinicians should NOT offer sipuleucel-T